Autonomix Medical financials
$3.75−2.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$17.0M | -$11.6M | -$7.5M |
| Net income | -$16.7M | -$11.4M | -$15.4M |
| Net margin | — | — | — |
| Diluted EPS | $-48.72 | $-135.66 | $-311.22 |
| EBITDA | -$17.0M | -$11.4M | -$7.5M |
| Operating cash flow | -$12.3M | -$8.3M | -$6.6M |
| Free cash flow | -$12.3M | -$8.3M | -$6.7M |
| Diluted shares | 0.3M | 0.1M | 0.0M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|
| Cash & equivalents | $7.0M | $9.1M | $8.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $1.0M |
| Total assets | $7.6M | $9.8M | $9.4M |
| Total liabilities | $1.7M | $1.7M | $1.8M |
| Shareholders' equity | $5.9M | $8.1M | $7.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology